Endonovo Therapeutics, Inc.
Balance Sheet
| Line Item | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $0 | $32.6K | $10.9K | $98 | $23.1K | — | $60.0K | $85.9K |
| Accounts Receivable | — | — | $3.1K | — | $944 | $945 | $945 | $944 |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $35.5K | $72.8K | $95.2K | $15.8K | $24.1K | $5.9K | $64.4K | $94.9K |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $780.3K | $942.0K | $1.1M | $1.3M | $1.4M | $1.6M | $1.8M | $1.9M |
| Total Assets | $815.8K | $1.0M | $1.2M | $1.3M | $1.5M | $1.6M | $1.8M | $2.0M |
| Liabilities | ||||||||
| Accounts Payable | — | — | — | $884.2K | $865.8K | $786.0K | $704.0K | $658.5K |
| Total Current Liabilities | $23.7M | $23.1M | $25.5M | $33.4M | $21.0M | $20.7M | $19.8M | $17.7M |
| Long-Term Debt | $7.1M | $7.1M | $6.9M | $7.2M | $7.3M | $7.4M | $7.4M | $7.3M |
| Total Liabilities | $23.8M | $23.2M | $25.6M | $33.5M | $21.1M | $20.8M | $19.9M | $17.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-66.6M | $-65.9M | $-67.9M | $-75.1M | $-62.0M | $-61.4M | $-58.9M | $-56.4M |
| Total Stockholders' Equity | $-23.0M | $-22.4M | $-24.4M | $-32.2M | $-19.6M | $-19.2M | $-18.0M | $-15.8M |